trabodenoson/latanoprost / Rocket Pharma - LARVOL DELTA

Inotek completes patient recruitment in phase 2 trial of a fixed-dose combination (FDC) of trabodenoson and latanoprost (Businesswire) - "Inotek Pharmaceuticals...announced the completion of the active recruitment phase of the Phase 2 dose-ranging trial of a fixed-dose combination (FDC) of trabodenoson and latanoprost for the treatment of glaucoma...Top-line data from the FDC study are expected in July."

Enrollment closed • P2 data • Glaucoma • Ophthalmology

Inotek Pharmaceuticals announces top-line results of phase 2 fixed-dose combination trial of trabodenoson and provides corporate update (Businesswire) - P2, N=201; "After 28 Days...the fixed combination of trabodenoson 3% and latanoprost 0.005% showed a 1.2 mmHg improvement in intraocular pressure (IOP) reduction compared to the latanoprost 0.005% alone (p=0.061 for the mean comparison, p=0.020 for the median comparison). However, at Day 56, after 4 additional weeks of treatment and night-time dosing (QPM), no meaningful clinical advantage in IOP reduction for the fixed dose combinations was observed."

P2 data • Glaucoma • Ophthalmology

Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma (clinicaltrials.gov) - P2; N=165; Not yet recruiting; Sponsor: Inotek Pharmaceuticals Corporation

New P2 trial • Biosimilar • Cardiovascular • Glaucoma • Ophthalmology